MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis

John Mascarenhas(Tisch Hospital), Vikas Gupta(Indian Institute of Technology Kanpur), Jean‐Jacques Kiladjian(Délégation Paris 5), Francesco Passamonti(University of Milan), Moshe Talpaz(University of Michigan), Gabriella Hobbs(Harvard University), Gozde Colak(Morpho (United States)), Jike Cui(Morpho (United States)), Nikki Granacher(Ziekenhuisnetwerk Antwerpen Stuivenberg), Adam J. Mead(National Institute for Health and Care Research), Andrea Patriarca(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), Natalia Curto‐García(Guy's and St Thomas' NHS Foundation Trust), Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), Marina Kremyanskaya(Tisch Cancer Institute), Joseph M. Scandura(Cornell University), Raajit K. Rampal(Memorial Sloan Kettering Cancer Center), Srđan Verstovšek(Unknown), Tim C. P. Somervaille(University of Manchester), Timothy Devos(Rega Institute for Medical Research), Francesca Palandri(Istituto Oncologico Romagnolo), Mariëlle J. Wondergem(Amsterdam UMC Location Vrije Universiteit Amsterdam), Ronald Hoffman(Icahn School of Medicine at Mount Sinai)
Journal of Clinical Oncology
March 7, 2023
Cited by 89


Related Papers